Krystal Biotech, Inc. (KRYS)

Krystal Biotech's stock price has been positively impacted by strong financial performance and analyst sentiment. The company reported strong Q1 2026 earnings with an EPS of $1.83 and revenue of $116.4 million, exceeding expectations, driven by a 32% year-over-year increase in net product revenue from VYJUVEK. The stock price reached an all-time high of $302 on May 5, 2026. The company also reported strong Q4 2025 earnings with an EPS of $1.70 and revenue of $107.11 million. Krystal Biotech's stock has shown a significant 1-year return of 76.81% and a year-to-date return of 11.93% as of April 22, 2026. Institutional ownership is high.

Information regarding the demand seasonality for Krystal Biotech, Inc.'s products and services is not explicitly available. Implied volatility for KRYS stock tends to rise in April and decline to its lowest levels in September, which relates to stock market behavior rather than product demand.

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on genetic medicines for diseases with high unmet medical needs. The company's core strategy revolves around its proprietary redosable Herpes Simplex Virus vector gene therapy platform. Its flagship product is VYJUVEK, a gene therapy for Dystrophic Epidermolysis Bullosa. Krystal Biotech has an extensive pipeline of product candidates, including KB803 for ocular complications of dystrophic epidermolysis bullosa, KB801 for neurotrophic keratitis, KB407 for Cystic Fibrosis, KB111 for Hailey-Hailey disease, KB707 for solid tumors, KB304 for dynamic wrinkles, KB408 for Alpha-1 Antitrypsin Deficiency, and KB301 for aesthetic skin conditions.

Krystal Biotech, Inc. is headquartered in Pittsburgh, Pennsylvania, United States. Its primary commercial operations for VYJUVEK are in the United States, and it is expanding globally into markets like Germany, France, and Japan. The company operates two U.S. GMP facilities, Astra and Ancoris, for in-house manufacturing of its gene therapies.

Krystal Biotech has a strong brand reputation due to its successful transition to a commercial-stage biotechnology company. The company emphasizes its pioneering role in developing redosable genetic medicines and its HSV-1 vector platform. The FDA approval and commercial success of VYJUVEK have bolstered its reputation. Favorable analyst sentiment and a robust clinical pipeline also contribute to its strong standing. No negative events impacting Krystal Biotech's reputation were found.

Krystal Biotech, Inc. has a highly concentrated ownership structure, with institutional investors holding over 86% of shares. Major institutional owners include Fmr Llc, BlackRock, Inc., Avoro Capital Advisors LLC, The Vanguard Group, Inc., State Street Global Advisors, Inc., Soleus Capital Management, L.P., Capital World Investors, Redmile Group, LLC, Hood River Capital Management LLC, and Geode Capital Management, Llc. Company insiders hold approximately 11.86% of shares.